MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OCGN stock logo

OCGN

Ocugen, Inc.

$1.32
-0.05
 (-3.65%)
Exchange:  NASDAQ
Market Cap:  447.625M
Shares Outstanding:  112.236M
Delayed data
Calculate OCGN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Shankar Musunuri
Full Time Employees:  116
Address: 
263 Great Valley Parkway
Malvern
PA
19355
US
Website:  https://www.ocugen.com
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company’s developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company’s corporate headquarters are situated in Malvern, Pennsylvania.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/06 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,0364,0554,413
Gross Profit5,3322,0872,024
EBITDA-62,374-52,086-60,269
Operating Income-65,531-54,757-62,916
Net Income-63,078-54,054-67,846

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets64,54782,44243,516
Total Liabilities23,98352,81056,455
Total Stockholders Equity40,56429,632-12,166
Total Debt6,94132,50333,144
Cash and Cash Equivalents39,46258,51418,571

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-62,054-42,142-56,964
Capital Expenditure-10,476-3,385-185
Free Cash Flow-72,530-45,527-57,149
Net Income-63,078-54,054-67,846
Net Change in Cash-38,10119,359-39,934

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)199,626.569Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,977,916.314Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,148,248.750Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-1,786,749.788Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-119,775.941Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-688,949.250Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-34,648.391Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,438,254.924Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)468,262.064Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,331,881.607Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)19,868,256.946Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)7,660,961.154Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.560Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.790Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.120Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.055M  ?P/S
 (TTM)
: 
102.92
?Net Income
 (TTM)
: 
-54054000  ?P/E
 (TTM)
: 
-5.5
?Enterprise Value
 (TTM)
: 
459.298M  ?EV/FCF
 (TTM)
: 
-7.48
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
1688.22%  ?ROIC
 (TTM)
: 
-92.68%
?Net Debt
 (TTM)
: 
-26011000  ?Debt/Equity
 (TTM)
: 
-5.31
?P/B
 (TTM)
: 
-28.43  ?Current Ratio
 (TTM)
: 
0.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about OCGN valuation

Is Ocugen, Inc. (OCGN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Ocugen, Inc. (OCGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OCGN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OCGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OCGN’s P/E ratio?

You can see OCGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OCGN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OCGN a good long-term investment?

Whether OCGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OCGN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.65
MARKETSnap

Trading Metrics:

Open: 1.37   Previous Close: 1.37
Day Low: 1.32   Day High: 1.37
Year Low: 1   Year High: 2.73
Price Avg 50: 1.37   Price Avg 200: 1.51
Volume: 3.045M   Average Volume: 6.766M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
07-08-2026 14:21
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ocugen Q2 Earnings Call Highlights
07-08-2026 02:05
Ocugen Q2 Earnings Call Highlights
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
06-08-2026 17:04
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
10-07-2026 20:02
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
03-06-2026 12:51
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
03-06-2026 12:41
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read